Verrica Pharmaceuticals Inc. - Laporan Laba Rugi (TTM)

Verrica Pharmaceuticals Inc.

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Verrica Pharmaceuticals Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 12 12 12 12 0 1 9 9 9 9 3 5 9 14 9 8 7 15
Change (%) 0.00 0.00 0.00 -96.41 49.65 1,289.77 0.76 -4.36 -0.37 -62.77 59.93 73.95 56.04 -33.78 -17.85 -5.11 104.82
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 16 19 23 26 11 12 15 4 21 24 22 23 15 11 10
Change (%) 17.09 22.31 12.92 -55.50 0.73 27.36 -75.76 490.38 15.58 -8.22 1.62 -35.72 -23.08 -13.56
% of Revenue 132.74 4,327.61 3,537.05 287.39 126.92 133.68 170.88 111.24 410.64 272.86 160.48 246.28 192.70 156.22 65.93
Gross Operating Profit 12 12 12 -4 -18 -22 -17 -2 -3 -6 -0 -16 -15 -8 -13 -7 -4 5
Change (%) 0.00 0.00 -132.74 363.76 21.67 -24.23 -85.53 19.66 109.69 -94.10 4,321.39 -3.20 -45.40 60.15 -47.94 -42.46 -224.13
% of Revenue 100.00 100.00 100.00 -32.74 -4,227.61 -3,437.05 -187.39 -26.92 -33.68 -70.88 -11.24 -310.64 -172.86 -60.48 -146.28 -92.70 -56.22 34.07
SG&A 26 28 32 27 26 23 19 17 17 17 33 47 59 70 65 58 51 43
Change (%) 8.33 11.87 -14.70 -5.41 -8.27 -17.43 -9.95 -4.59 4.60 92.86 41.21 25.41 17.84 -6.83 -10.92 -12.91 -15.18
% of Revenue 217.48 235.59 263.56 224.82 5,920.88 3,629.30 215.63 192.70 192.24 201.84 1,045.54 923.20 665.60 502.66 707.25 766.88 703.87 291.49
R&D 16 16 15 -5 -9 -13 1 1 15 -4
Change (%) -0.46 -7.62 64.29 42.72 -111.61 0.00
% of Revenue 134.53 133.91 123.70 -1,244.08 -1,365.74 -140.25 16.16 16.90 467.38 -46.71
OpEx 42 44 46 43 39 37 33 30 30 32 52 68 84 92 84 73 62 53
Change (%) 4.97 4.81 -7.67 -9.55 -3.59 -13.08 -6.74 -2.36 8.32 62.23 31.34 22.38 10.26 -9.45 -13.07 -14.95 -14.89
% of Revenue 352.01 369.50 387.26 357.57 9,004.41 5,800.62 362.77 335.78 342.82 372.72 1,624.16 1,333.84 938.46 663.14 906.82 959.58 860.09 357.42
Operating Income -30 -32 -34 -31 -38 -37 -24 -21 -21 -23 -49 -63 -75 -78 -74 -65 -55 -38
Change (%) 6.94 6.59 -10.34 24.17 -4.19 -35.94 -9.59 -1.51 11.90 108.07 29.46 18.21 4.80 -5.12 -12.48 -16.10 -30.63
% of Revenue -252.01 -269.50 -287.26 -257.57 -8,904.41 -5,700.62 -262.77 -235.78 -242.82 -272.72 -1,524.16 -1,233.84 -838.46 -563.14 -806.82 -859.58 -760.09 -257.42
Interest Expense -4 -4 -4 -4 -4 -4 -3 -2 -1 -0 -2 -4 -6 -9 -9 -9 -9 -9
Change (%) 4.53 4.33 2.51 1.26 -1.52 -23.67 -33.56 -49.82 -92.84 2,024.36 139.11 58.53 37.70 8.31 0.47 -1.23 -2.55
% of Revenue -32.02 -33.47 -34.92 -35.79 -1,009.05 -664.03 -36.47 -24.05 -12.62 -0.91 -51.72 -77.32 -70.47 -62.19 -101.72 -124.40 -129.49 -61.61
Net Income -34 -36 -39 -35 -43 -41 -28 -24 -23 -23 -48 -67 -81 -87 -85 -77 -66 -49
Change (%) 7.00 6.48 -8.92 21.48 -3.77 -31.49 -12.84 -7.68 3.64 106.22 38.67 20.51 7.67 -2.23 -9.90 -13.83 -26.35
% of Revenue -281.73 -301.45 -320.98 -292.33 -9,887.24 -6,357.67 -313.42 -271.11 -261.70 -272.23 -1,507.90 -1,307.47 -905.83 -625.06 -922.81 -1,012.15 -919.21 -330.52

Source: Capital IQ

Other Listings
DE:1NE0
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista